| Ytd | -61.49% | |
| 1y | -64.57% |
| Open | 3.18 | Prev Close | 3.10 | Low | 3.05 | High | 3.18 | Mkt Cap | 58.44M |
| Vol | 62.38K | Avg Vol | 1.71M | EPS | -2.40 | P/E | -1.28 | Forward P/E | -1.96 |
| Beta | 1.30 | Short Ratio | 2.49 | Inst. Own | 5.82% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 5.56 | 200-d Avg | 8.62 | 1yr Est | 9.50 |
ELTX News
NEW YORK, July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 95.7% to $1.4 during Wednesday's
NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
BOSTON, July 06, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the
Gainers Chemomab Therapeutics (NASDAQ:CMMB) stock increased by 33.8% to $2.27 during Thursday's
Gainers Liminatus Pharma (NASDAQ:LIMN) stock increased by 40.9% to $0.16 during Thursday's pre-
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
Elicio Therapeutics, Inc. (Nasdaq: ELTX) ("Elicio" or the "Company"), a clinical-sta
BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the
LOS ANGELES--(BUSINESS WIRE)---- $ELTX--ELTX Investors Have Opportunity to Join Elicio Therapeutics,
NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
Ladenburg Thalmann analyst Kevin DeGeeter assumes Elicio Therapeutics (NASDAQ:ELTX) with a Buy ra
Smith & Wesson (SWBI) shares rose in pre-market trading after posting strong Q4 results, beating
Elicio Therapeutics Inc. (NASDAQ:ELTX) stock is up on Wednesday as the company reported promising cl
Elicio shares complete response data for ELI-002 7P in KRAS pancreatic cancer and plans combination
100% confirmed complete radiographic and complete metabolic responses in three patients who progress
100% confirmed complete radiographic and complete metabolic responses in three patients who progress
Elicio Therapeutics reported Q1 2026 results showing a widening net loss and zero revenue days befor
Elicio Therapeutics Inc. (NASDAQ:ELTX) stock is trading lower on Monday after disappointing results
Elicio Therapeutics reports mixed Phase 2 pancreatic cancer results, identifies key patient subgroup
ATLANTA, June 15, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Elicio Ther
US stocks gain on peace agreement with Iran, Nasdaq up 2%, Dow up 1.1%, S&P 500 up 1.54%. Tech s
US stocks rise on peace agreement with Iran, Dow up 600 points. Tech sector jumps, energy stocks dow
Elicio Therapeutics shares fell about 73% in early trading on Monday after the biotech firm's pancre
HC Wainwright & Co. analyst Robert Burns maintains Elicio Therapeutics (NASDAQ:ELTX) with a B
AMPLIFY-7P did not meet the pre-specified primary endpoint of disease-free survival ("DFS")
AMPLIFY-7P did not meet the pre-specified primary endpoint of disease-free survival ("DFS") in the i
B. Riley Securities analyst Mayank Mamtani initiates coverage on Elicio Therapeutics (NASDAQ:ELTX
BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “
In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal ade
BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the
